Form 4: Baker Bros. Advisors Acquires Warrants in TScan Therapeutics (TCRX) via Underwritten Offering

Baker Bros. Advisors and affiliated entities acquired warrants to purchase common stock of TScan Therapeutics through an underwritten offering, as disclosed in a Form 4 filing with the SEC.

Summary

• Baker Bros. Advisors LP, along with affiliated entities including 667, L.P. and Baker Brothers Life Sciences, L.P., reported the acquisition of warrants to purchase common stock of TScan Therapeutics, Inc. (TCRX) in a Form 4 filing with the SEC.
• The warrants were purchased on April 19, 2024, as part of an underwritten offering.
• 667, L.P. acquired 825,968 warrants, while Baker Brothers Life Sciences, L.P. acquired 8,851,451 warrants.
• The purchase price for the warrants was $7.1299 per share.
• The warrants are immediately exercisable at $0.0001 per share, but the holders' ownership is limited to a maximum percentage of 4.99% of the outstanding shares of common stock.
• The Funds may increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99% with written notice to the Issuer.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the securities held by 667, L.P. and Baker Brothers Life Sciences, L.P.
• Baker Bros. Advisors LP serves as the investment advisor to the Funds and has complete discretion over the investment and voting power of the securities.
• Dr. Stephen R. Biggar, an employee of Baker Bros. Advisors LP, is a director of TScan Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant warrant acquisition by a reputable investment firm, indicating confidence in the company's prospects. However, the limitations on warrant exercise and the lack of specific forward-looking statements temper the overall sentiment.

Positives

• Baker Bros.' investment signals confidence in TScan Therapeutics' prospects.
• The immediate exercisability of the warrants provides potential for quick conversion to common stock.
• The ability to increase the ownership percentage up to 19.99% offers flexibility for future investment.

Risks

• The exercise of the warrants is subject to ownership limitations, which could restrict the potential gains for Baker Bros.
• The investment is subject to the performance of TScan Therapeutics' stock.

Future Outlook

The document does not contain specific forward-looking statements regarding TScan Therapeutics' future performance, but the warrant acquisition suggests a positive outlook from Baker Bros. Advisors.

Industry Context

This investment reflects ongoing activity in the biotechnology sector, where strategic investments and warrant acquisitions are common methods for institutional investors to gain exposure to promising companies like TScan Therapeutics.

Comparison to Industry Standards

• Warrant acquisitions are a common investment strategy in the biotech industry, often used by firms like Baker Bros. to gain potential upside while managing risk.
• Similar transactions can be seen with other biotech companies where institutional investors acquire warrants as part of financing rounds or strategic investments.
• The exercise price of $0.0001 is typical for prefunded warrants, allowing immediate exercise upon issuance.

Stakeholder Impact

• The warrant acquisition could positively impact shareholders by increasing investor confidence.
• The capital raise benefits TScan Therapeutics by providing additional funding for operations and development.

Next Steps

• Baker Bros. may exercise the warrants to acquire common stock, subject to ownership limitations.
• Baker Bros. may adjust the maximum ownership percentage with written notice to TScan Therapeutics.
• Continued monitoring of TScan Therapeutics' performance and stock price.

Key Dates